The ENA test is an ELISA assay for the qualitative determination of IgG autoantibodies against a mix of seven highly specific extractable nuclear antigens (ENA), for the differential diagnosis of systemic autoimmune connective tissue diseases (SARD). The antigens included are: ribosomal P protein, nRNP/Sm, Sm, SS-A (Ro60), SS-B (La), Scl-70, Jo-1 and CENP-B.
The ENA test serves as an initial antibody profile screening in ANA-positive patients, as it identifies autoantibodies associated with specific autoimmune diseases:
- Sm and RNP/Sm: highly specific for SLE and MCTD
• SS-A and SS-B: Sjögren’s syndrome and SLE
• Scl-70 and CENP-B: diffuse and limited forms of systemic sclerosis
• Jo-1: anti-synthetase syndrome
• Ribosomal P protein: associated with SLE with neuropsychiatric involvement
Compared to broader screening panels, the ENA panel allows for better nosological classification, to support a clinically relevant and more specific diagnosis.
Serum, EDTA plasma, heparin plasma, citrate plasma
ELISA
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.